Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Research & Development (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Research & Development data on record, last reported at $3.2 million in Q3 2025.

  • For Q3 2025, Research & Development fell 47.81% year-over-year to $3.2 million; the TTM value through Sep 2025 reached $22.1 million, down 19.56%, while the annual FY2024 figure was $26.7 million, 32.66% down from the prior year.
  • Research & Development reached $3.2 million in Q3 2025 per RANI's latest filing, down from $5.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $12.0 million in Q3 2021 and bottomed at $3.2 million in Q3 2025.
  • Average Research & Development over 5 years is $7.6 million, with a median of $7.6 million recorded in 2024.
  • Peak YoY movement for Research & Development: soared 472.2% in 2021, then plummeted 47.81% in 2025.
  • A 5-year view of Research & Development shows it stood at $7.4 million in 2021, then soared by 40.03% to $10.4 million in 2022, then fell by 26.77% to $7.6 million in 2023, then decreased by 10.48% to $6.8 million in 2024, then plummeted by 52.69% to $3.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $3.2 million in Q3 2025, $5.5 million in Q2 2025, and $6.6 million in Q1 2025.